NYSE:TARO - Taro Pharmaceutical Industries Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Taro Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $92.83 -0.36 (-0.39 %) (As of 12/16/2019 06:00 AM ET) Add Compare Today's Range$92.23Now: $92.83▼$94.0850-Day Range$75.43MA: $87.21▼$97.9452-Week Range$72.97Now: $92.83▼$109.42Volume54,478 shsAverage Volume145,040 shsMarket Capitalization$3.58 billionP/E Ratio12.84Dividend YieldN/ABeta0.53 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:TARO Previous Symbol CUSIPN/A CIK906338 Webhttp://www.taro.com/ Phone972-4847-5700Debt Debt-to-Equity RatioN/A Current Ratio7.06 Quick Ratio6.36Price-To-Earnings Trailing P/E Ratio12.84 Forward P/E Ratio14.39 P/E GrowthN/A Sales & Book Value Annual Sales$669.89 million Price / Sales5.34 Cash Flow$7.76 per share Price / Cash Flow11.96 Book Value$49.59 per share Price / Book1.87Profitability EPS (Most Recent Fiscal Year)$7.23 Net Income$281.78 million Net Margins40.43% Return on Equity14.13% Return on Assets12.72%Miscellaneous Employees1,464 Outstanding Shares38,540,000Market Cap$3.58 billion Next Earnings Date2/5/2020 (Estimated) OptionableOptionable Receive TARO News and Ratings via Email Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter. TARO Rates by TradingView Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions What is Taro Pharmaceutical Industries' stock symbol? Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO." How were Taro Pharmaceutical Industries' earnings last quarter? Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced its quarterly earnings results on Monday, November, 4th. The company reported $1.46 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.72 by $0.26. The firm had revenue of $160.85 million for the quarter, compared to the consensus estimate of $168.60 million. Taro Pharmaceutical Industries had a net margin of 40.43% and a return on equity of 14.13%. View Taro Pharmaceutical Industries' Earnings History. When is Taro Pharmaceutical Industries' next earnings date? Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Taro Pharmaceutical Industries. What price target have analysts set for TARO? 1 brokers have issued 1-year target prices for Taro Pharmaceutical Industries' shares. Their forecasts range from $110.00 to $110.00. On average, they anticipate Taro Pharmaceutical Industries' share price to reach $110.00 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries. What is the consensus analysts' recommendation for Taro Pharmaceutical Industries? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries. Has Taro Pharmaceutical Industries been receiving favorable news coverage? Media headlines about TARO stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Taro Pharmaceutical Industries earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Taro Pharmaceutical Industries. Are investors shorting Taro Pharmaceutical Industries? Taro Pharmaceutical Industries saw a increase in short interest in November. As of November 29th, there was short interest totalling 297,400 shares, an increase of 6.5% from the November 14th total of 279,200 shares. Based on an average trading volume of 79,500 shares, the days-to-cover ratio is presently 3.7 days. Approximately 3.3% of the shares of the stock are short sold. View Taro Pharmaceutical Industries' Current Options Chain. Who are some of Taro Pharmaceutical Industries' key competitors? Some companies that are related to Taro Pharmaceutical Industries include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Catalent (CTLT), Sarepta Therapeutics (SRPT) and Perrigo (PRGO). What other stocks do shareholders of Taro Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Broadcom (AVGO), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), Supernus Pharmaceuticals (SUPN), Celgene (CELG), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (nbix) and Southwest Airlines (LUV). Who are Taro Pharmaceutical Industries' key executives? Taro Pharmaceutical Industries' management team includes the folowing people: Mr. Uday V. Baldota, CEO & Director (Age 49)Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)Mr. Itzik Baruch, VP of Technical Services (Age 56)Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72) Who are Taro Pharmaceutical Industries' major shareholders? Taro Pharmaceutical Industries' stock is owned by a variety of of institutional and retail investors. Top institutional investors include CLARET ASSET MANAGEMENT Corp (0.22%), Millennium Management LLC (0.21%), California Public Employees Retirement System (0.11%), Systematic Financial Management LP (0.02%) and Squarepoint Ops LLC (0.01%). Which institutional investors are selling Taro Pharmaceutical Industries stock? TARO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, CLARET ASSET MANAGEMENT Corp and Systematic Financial Management LP. Which institutional investors are buying Taro Pharmaceutical Industries stock? TARO stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Squarepoint Ops LLC. How do I buy shares of Taro Pharmaceutical Industries? Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Taro Pharmaceutical Industries' stock price today? One share of TARO stock can currently be purchased for approximately $92.83. How big of a company is Taro Pharmaceutical Industries? Taro Pharmaceutical Industries has a market capitalization of $3.58 billion and generates $669.89 million in revenue each year. The company earns $281.78 million in net income (profit) each year or $7.23 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.View Additional Information About Taro Pharmaceutical Industries. What is Taro Pharmaceutical Industries' official website? The official website for Taro Pharmaceutical Industries is http://www.taro.com/. How can I contact Taro Pharmaceutical Industries? Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected] MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 232 (Vote Outperform)Underperform Votes: 262 (Vote Underperform)Total Votes: 494MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2019 by MarketBeat.com StaffFeatured Article: What is the 52-week high/low?